NASDAQ OMX

VistaJet's US Customer Base Trebles - Reinforcing Its Commanding Position in the Market

Del

Following strong Q3 results in North America, VistaJet aims to amplify its efforts and resources to continue the positive momentum in the region

 

For North America ending September 30:

  • New Program customers increased three times year over year
  • New Program hours increased 146% year over year
  • Flight departures increased by 30% in Q3 '17 v. Q3 '16
  • Q3 '17 Program hours increased 210% v. Q3 '16
  • 45% of Program customers who have joined in past 12 months have booked additional hours
  • Today's results follow $150 million investment from Rhône Capital

LAS VEGAS, Oct. 09, 2017 (GLOBE NEWSWIRE) -- VistaJet, the first and only global aviation company, is delighted to announce a set of results that highlights the significant progress made in the US throughout the third quarter ending September 30, 2017. Driving the growth is the company's flagship Program Membership, registering three times more clients year over year, resulting in a 146% increase in Program hours. Moreover, flight hours sold to Program members grew significantly over the period with an increase of 210% compared to Q3 '16. In addition to VistaJet's marked rise in new US passengers, 45% of those who joined as Program customers have gone on to increase the total number of hours flown.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/ef21bfc7-9dc9-4c61-a5c1-f7474fef077d

VistaJet's Q3 announcement reinforces the global trend of individuals and corporations moving away from aircraft ownership as they look to shed costs and asset risks, but not the comfort, convenience and benefits of private aviation. Following the $150 million investment from Rhône Capital - which now values VistaJet in excess of $2.5 billion - the company is well positioned to conquer even more fractional and full aircraft owners in the US market, by offering global coverage, consistent unparalleled quality and maximum efficiency.

Thomas Flohr, VistaJet's Founder and Chairman, stated, "We're extremely pleased to announce today's update as it is evidence of the exponential progress VistaJet is making in the US, the core market of private aviation. The numbers we see show two very important things about private aviation in the US. First, there continues to be a trend away from owning aircraft, either entirely or a fraction, given the associated costs and assets risk. Second, demand for high quality private aviation services continues to grow, proven by our ability to treble the number of US Program customers. US customers, both corporate and individual, are discovering that VistaJet is the new generation of business aviation solution. We are leading the industry by building services around the new shared-economy customers, while we keep offering the highest service level, and delivering it in the most efficient manner."

As a result of the company's continued success in the region, VistaJet also announces that it will increase its dedicated US fleet by 50%, to support its growing clients' demand.

To showcase VistaJet's fleet of luxury aircraft, bespoke services and curated details, the company will meet prospective customers in six US cities on board one of its Bombardier Global 5000 aircraft. The tour will allow selected prospective clients to try the VistaJet experience, as have 250,000 passengers already, flying to over 1,600 airports in 187 countries (or 96% of the world). Between October 16-23, a VistaJet Global 5000 will visit Los Angeles, San Francisco, Seattle, Chicago, Boston and New York.

About VistaJet
VistaJet is the first and only global aviation company. On its fleet of silver and red business jets, VistaJet has flown corporations, governments and private clients to 187 countries worldwide. Founded in 2004 by Thomas Flohr, the company pioneered an innovative business model where customers pay only for the hours they fly, free of the responsibilities and asset risks linked to aircraft ownership. VistaJet's signature Program service offers customers a bespoke subscription of flight hours on its fleet of mid and long-range jets, to fly them anywhere and at any time.

More VistaJet information and news: www.vistajet.com.
VistaJet Investor information: www.vistajet.com/investors/
VistaJet Direct information: https://www.vistajet.com/direct/

Contact Information:

DKC
Liz Anklow 
Executive Vice President
T: +1.212.981.5103
Liz_Anklow@dkcnews.com

VistaJet
Michael Salamanca
Regional Marketing Manager, The Americas
T: +1.917.755.3734
Michael.Salamanca@vistajet.com

Statements in this release are based solely upon information available as of the date of this release, are not a comprehensive statement of the Company's financial results or positions as of or for the 2017 fiscal year, and have not been audited, reviewed, or compiled by independent registered accounting firm. Therefore, the financial information in this release is preliminary, unaudited and subject to revision upon completion of the Company's closing and audit processes. The company assumes no obligation to update any information contained herein, save for any information required to be disclosed by law.




This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: VistaJet Ltd via Globenewswire

Om NASDAQ OMX

NASDAQ OMX
NASDAQ OMX
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ OMX (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra NASDAQ OMX

Registrer deg med din epostadresse under for å få de nyeste sakene fra NASDAQ OMX på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra NASDAQ OMX

Barings Supports New Mountain Capital Investment in DRB Systems17.10.2017 16:30Pressemelding

CHARLOTTE, N.C., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Barings, one of the world's leading asset management firms, announced today that it served as a Joint Lead Arranger on a Senior Secured Credit Facility to support New Mountain Capital's acquisition of DRB Systems LLC.                                                               Founded in 1984 and based in Akron, Ohio, DRB Systems is the leading provider of turnkey technology solutions used to enhance the operational efficiency of car wash sites across the U.S.  DRB's integrated technology offering includes hardware and software used in point-of-sale and tunnel control systems as well as ancillary modules to support marketing, human resources, and business analytics. "New Mountain Capital is pleased to have completed its investment in DRB Systems," said Jack Qian, Director of New Mountain Capital. Laura Holson, Head of Capital Markets at New Mountain added, "We deeply value Barings' support as a financing pa

Crown Bioscience to Showcase Scientific Expertise in Preclinical Evaluation of Investigational Cancer Compounds17.10.2017 16:12Pressemelding

SANTA CLARA, Calif., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:ticker 6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, will showcase their scientific expertise at this year's American Association for Cancer Research's International Conference on Molecular Targets and Cancer Therapeutics (AACR-NCI-EORTC) October 26th through the 30th. CrownBio's scientists will present 13 scientific posters describing their latest research efforts, including generation of novel models for combinatory chemotherapy and immunotherapy studies, creation of 3D screening panels for improved efficacy assessments, demonstration of a checkpoint immunotherapy modulating intestinal microbiota, among other innovative developments in cancer therapeutics and preclinical pharmacology evaluation. On

Oxford Immunotec Schedules Third Quarter 2017 Earnings Release and Conference Call for October 31, 201717.10.2017 15:15Pressemelding

OXFORD, United Kingdom and MARLBOROUGH, Mass., Oct. 17, 2017 (GLOBE NEWSWIRE) -- Oxford Immunotec Global PLC (Nasdaq:OXFD), a global, high-growth diagnostics company focused on developing and commercializing proprietary tests for the management of underserved immune-regulated conditions, today announced that it plans to release third quarter 2017 financial results prior to market open on Tuesday, October 31, 2017.  Dr. Peter Wrighton-Smith, Chief Executive Officer, and Rick Altieri, Chief Financial Officer, will host a conference call to review the Company's results at 8:00 a.m. Eastern Time the same day. The call will be concurrently webcast. To listen to the conference call on your telephone, please dial (855) 363-5047 for United States callers and +1 (484) 365-2897 for international callers and reference confirmation code 99539511, approximately ten minutes prior to start time.  To access the live audio webcast or subsequent archived recording, visit the Investor Relations se

World Conference on Lung Cancer Tuesday Press Conference: Evidence to Support Innovative Lung Cancer Interventions17.10.2017 08:16Pressemelding

YOKOHAMA, Japan, Oct. 17, 2017 (GLOBE NEWSWIRE) -- Today's press conference at the International Association for the Study of Lung Cancer (IASLC) 18th World Conference on Lung Cancer (WCLC) featured groundbreaking findings in the study of both small cell and non-small cell lung cancer. The studies presented covered broad research areas, from confirmation of existing classification criteria to ensuring viability of evidence to supporting the use of specific interventions. Biopsy specimen found to be reliable for evaluating DLL3 expression in small cell lung cancer Small cell lung cancer (SCLC) biopsy specimen was found to be reliable material for evaluating DLL3 expression; high levels of DLL3 in SCLC are correlated with poor survival trends. These results may lead to further evaluation of the scoring system for predicting DLL3-targeted therapeutic efficacy and clinical significance of DLL3 expression in high-grade pulmonary neuroendocrine carcinomas.

New Era Launches Direct-to-Consumer eCommerce Site Built by EPAM and Powered with SAP Hybris17.10.2017 06:01Pressemelding

New Site Expands Headwear and Apparel Offering with Immersive, Omnichannel Experience NEWTOWN, Pa., Oct.  17, 2017  (GLOBE NEWSWIRE) -- EPAM Systems, Inc. (NYSE:EPAM), a leading global provider of digital platform engineering and software development services, and New Era, a global headwear brand rooted in sports, today announced the launch of New Era's first direct-to-consumer website, neweracap.com. New Era's B2B business remains strong, and the company is now putting an emphasis on selling its products directly to customers and expanding its offering into the lifestyle market. The new site offers products for seasoned athletes and sports fans, as well as street and lifestyle consumers. "In an age where businesses cannot tolerate lengthy, scope changing technology projects, EPAM quickly established themselves as the standout partner for us to tackle this ambitious initiative," said Lorenz Gan, Global Vice President, Information Technology, New Era. "Whilst this p

LogicBio Therapeutics to Present Preclinical Data at European Society of Gene & Cell Therapy 25th Anniversary Congress in Berlin16.10.2017 15:00Pressemelding

· Company co-founder Professor Adi Barzel, Ph.D., to present new proof-of-concept efficacy data CAMBRIDGE, Massachusetts, Oct. 16, 2017 (GLOBE NEWSWIRE) -- LogicBio Therapeutics, Inc., a gene-therapy company with a mission to develop cures for early-onset life-threatening diseases, announced today that its company co-founder, Dr. Adi Barzel, will present new data from its genome-editing platform during the 25th Annual European Society of Gene & Cell Therapy (ESGCT) Congress in two presentations this Wednesday in Berlin, Germany. The ESGCT will be held from October 17-20, 2017, at the bcc Berlin. Dr. Barzel will present data in multiple animal models of disease demonstrating the extended therapeutic potential of LogicBio's proprietary GeneRide(TM) platform technology. The GeneRide technology harnesses the natural power of homologous recombination to enable precise, site-specific in vivo genome editing to deliver therapeutic genetic material without th

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom